Epilepsy with Eyelid Myoclonia

Epilepsy with eyelid myoclonia (EEM) is a genetic generalised epilepsy syndrome characterised by rapid eyelid jerks, usually triggered by eye closure in light, often together with brief absence seizures and photosensitivity. It was previously widely known as Jeavons syndrome.

The syndrome is frequently under-recognised because eyelid myoclonia can be mistaken for blinking, tics, eye-rolling or behavioural mannerisms.

The defining seizure

Eyelid myoclonia consists of brief, rapid jerking of the eyelids, often with upward deviation of the eyes and sometimes slight backward movement of the head.

Awareness may be preserved or briefly impaired. Eyelid myoclonia with or without absence seizures is mandatory for the syndrome diagnosis.

Eye closure matters

A distinctive feature is that eye closure in the presence of light can trigger the characteristic clinical event or generalised EEG discharge.

This is different from simply having seizures in darkness or being sensitive to all visual stimulation.

Photosensitivity

Photosensitivity is common, especially in younger untreated patients. Intermittent photic stimulation during EEG may provoke generalised polyspike-wave activity and eyelid myoclonia.

Photosensitivity can become less obvious with age or antiseizure treatment.

Typical age at onset

The ILAE childhood syndrome criteria exclude onset below 2 years or above 14 years for classic EEM. International expert consensus describes the usual clinical onset as between about 3 and 12 years.

Because eyelid myoclonia may be subtle, the syndrome can remain undiagnosed for years.

Other seizure types

Typical absence seizures and generalised tonic-clonic seizures can occur.

Focal seizures or atonic seizures should lead clinicians to reconsider whether another syndrome better explains the presentation.

The EEG pattern

EEG characteristically shows fast generalised polyspike or polyspike-and-wave complexes, often around 3–6 Hz, triggered by eye closure and/or intermittent photic stimulation.

The background is usually normal. Persistent focal slowing or consistently unilateral epileptiform activity should prompt consideration of another diagnosis.

Why EEG technicians and clinicians can miss it

The eyelid movements are brief and can be mistaken for muscle artefact. If the clinical event and EEG are not viewed together, the diagnostic significance may be overlooked.

Video-EEG is especially useful because it links the visible eyelid movement with the generalised discharge.

MRI

MRI is not required in a classic presentation and should be normal aside from incidental findings.

A causative structural lesion would argue against EEM as the primary syndrome diagnosis.

Genetics

EEM is considered genetic, but one single gene does not explain most cases.

International expert consensus supports genetic testing particularly when there is intellectual disability, drug-resistant epilepsy or a strong family history.

Distinguishing EEM from childhood absence epilepsy

Both can produce brief absence seizures and generalised spike-wave activity.

The key difference is the prominent eyelid myoclonia, eye-closure sensitivity and photosensitivity in EEM.

Distinguishing EEM from juvenile myoclonic epilepsy

JME can also be photosensitive, but its defining myoclonus affects the limbs, especially after waking.

Prominent eyelid myoclonia points toward EEM, whereas recurrent morning arm jerks suggest JME.

Treatment evidence

Randomised treatment trials are limited, so much of the management evidence comes from observational data and international expert consensus.

A 2023 international panel reached strong consensus that valproate, levetiracetam and lamotrigine can be effective, with valproate considered the drug of choice in people for whom it is appropriate.

Reproductive considerations

Because valproate carries major reproductive risks, levetiracetam or lamotrigine may be preferred alternatives in people who could become pregnant.

Regulatory restrictions vary internationally and should be interpreted according to local law and prescribing guidance.

Medicines that may worsen EEM

The international expert panel reached strong consensus to avoid sodium-channel-blocking medicines other than lamotrigine because they may worsen seizure control.

This is another reason accurate syndrome classification matters.

Ethosuximide and clobazam

The same consensus found moderate agreement that ethosuximide and clobazam can be effective in some people.

No single medicine controls all seizure types in every patient.

Drug resistance

Drug-resistant epilepsy is not rare. Expert consensus suggests that more than one quarter of affected people may have persistent seizures despite treatment.

At the same time, some people achieve good control, so the syndrome should not be portrayed as uniformly severe.

Persistence into adulthood

Unlike many cases of childhood absence epilepsy, EEM frequently persists beyond childhood. Remission is not expected in most people before adulthood, and some remain treatment-dependent long term.

Psychosocial impact

Eyelid myoclonia without obvious loss of awareness may still be socially intrusive and distressing. Frequent visible eye movements can attract attention, be mistaken for behaviour or affect confidence.

Treatment goals should therefore include the person’s own experience rather than focusing only on convulsive seizures.

Worldwide diagnosis

ILAE criteria recognise that in resource-limited regions EEM may sometimes be diagnosed clinically when the examiner has witnessed characteristic eyelid myoclonia or seen it clearly on home video and other mandatory and exclusionary features fit.

EEG remains strongly desirable, but this flexibility matters where EEG and photic stimulation are not readily available.

The central point

EEM is not simply “blinking during an absence”. Eyelid myoclonia, eye-closure sensitivity and photosensitivity form a distinctive syndrome that is often missed for years.

Sources

Medical note: photosensitivity and blinking alone do not diagnose EEM. Diagnosis depends on the full clinical and EEG pattern.

Evidence checked: September 2026.